ASM Microbe

New Orleans, LA

June 3, 2017

Crestone presents Phase 1 data from single and multiple ascending dose clinical trials with CRS3123, at the ASM Microbe Meeting in New Orleans. CRS3123 is a drug candidate in development for the treatment of C. difficile infections.

Learn More:

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123

Phase I Trial of a Single Dose of CRS3123